Q9(R1) Quality Risk Management

June 15, 2022

Guidance Document

June 2022

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page. The draft guidance has been left in the original International Council for Harmonization format. The final guidance will be reformatted and edited to conform with FDA’s good guidance practice regulation and style.

 

Download the Draft Guidance Document

Draft

Not for implementation.
Contains non-binding recommendations.

This guidance is being distributed for comment purposes only.

Read the Federal Register Notice

Interested in learning more? Contact us today to find out how we can help not only with your EMA/FDA submissions, but all of your global regulatory needs.




FDA North America

June 15, 2022

Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies

Guidance Document Draft Guidance for Industry June 2022 This guidance describes a standards recognition program for regenerative medicine therapies (SRP-RMT) at FDA’s Center for Biologics Evaluation...

Read More
FDA North America

June 15, 2022

FDA Issues Draft Guidance for Industry, Considerations for Rescinding Breakthrough Therapy Designation

Draft Guidance June 24, 2022 The U.S. Food and Drug Administration issued a draft guidance for industry titled Considerations for Rescinding Breakthrough Therapy Designation. This draft guidance...

Read More
FDA North America

June 15, 2022

Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--“Dose Banding”

Draft Guidance July 2022 This guidance is intended to assist applicants in incorporating dose banding information into the drug labeling provided in a new drug application (NDA) submitted under the...

Read More